Is Kyprolis® (carfilzomib) a treatment option for a first relapse of myeloma?

 

In this week’s video, Dr. Brian GM Durie talks about benefits and risks of the combination therapies of Kyprolis and dexamethasone (Kd), and Kyprolis, Revlimid, and dexamethasone (KRd).

BOTTOM LINE:
Kyprolis as a doublet or as a triplet is an excellent option, but work with your doctor to monitor its possible side effects.

If you have a question that you’d like to suggest for a future episode of Ask Dr. Durie, please submit it to [email protected]

To reach the IMF InfoLine Coordinators, please call 800.452.2873 or email them at [email protected]


Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Video
IMF TV Blog Category
Old Id
747

Source URL: https://www.myeloma.org/videos/kyprolisr-carfilzomib-treatment-option-first-relapse-myeloma